Board Change


C4X Discovery Holdings plc

(“C4XD”, “C4X Discovery” or the “Company”)

19 November 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that Craig Fox, Chief Scientific Officer (“CSO”), has informed the Company of his intention to step down from his role and the Board, after six years of service, to pursue a new opportunity. Craig is expected to leave the Company by 31 March 2022 and a search for a new CSO has commenced. A further announcement will be made in due course.

Clive Dix, Chief Executive Officer of C4X Discovery, commented:

“Craig has been an important part of the C4XD team and his scientific know-how and expertise has contributed to a plethora of exciting scientific discoveries that have led to the signing of major outlicensing agreements. On behalf of the Board, I would like to express my sincere gratitude to Craig for his dedication and valuable contribution to the Company during his six years of service. We wish Craig continued success in all his future endeavours.”

Craig Fox commented:

“I have thoroughly enjoyed my time at C4XD, and it has been a privilege to work with its fantastic people and to see the Company transform through its AIM-listing and subsequent multiple partnering deals. I believe the team’s world-class scientific expertise, tenacity, and dedication, combined with proprietary cutting-edge technologies provide a truly ground-breaking capability that can efficiently deliver world-leading medicines that can meaningfully impact the lives of patients. I wish the team well as I move on to my next role and look forward to hearing about their next achievements.”

C4X Discovery Holdings plc

Mo Noonan, Communications +44 (0)7876 444 977

Panmure Gordon (UK) Limited (NOMAD and Broker) 

Freddy Crossley, Emma Earl (Corporate Finance) +44 (0)20 7886 2500
Rupert Dearden (Corporate Broking)

Consilium Strategic Communications

Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700

C4X Discovery (“C4XD”) is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.